Among RAS mutant cancer cell lines, KRASG12X and NRAS glutamine 61 mutant (NRASQ61X) cells were significantly more sensitive compared with cell lines with other oncogenic KRAS or NRAS mutations, respectively (Wilcoxon rank-sum test with continuity correction, Fig. 1D). This evidence concerns the gene KRAS and cancer.